• By Steven Muntner, Beth Allan, and Deanna Kamienski
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
Oxford Immunotec Global PLC is paying $6mm in cash to acquire Immunetics Inc. (immunoassays for infectious diseases). Oxford could also shell out up to $6mm in cash upon attaining certain revenue goals and development milestones over the next three years. (Oct.)
Immunetics offers rapid, cost-effective ELISA and Western Blot tests that are highly specific and sensitive. Its BacTx is a colorimetric...
